Full-Time

Lead UI/UX Designer

Niagen Bioscience

Niagen Bioscience

51-200 employees

Advances NAD+ science; consumer products

Compensation Overview

$130k - $165k/yr

Westwood, CA, USA

Hybrid

Category
UI/UX & Design (1)
Required Skills
UI/UX Design
Adobe Creative Suite
Figma
A/B Testing
Sketch
Graphic Design

Get referred to Niagen Bioscience

Find people who can refer or advise you

Requirements
  • 5+ years of dedicated UI/UX design experience, with at least 2 years leading design at a DTC e-commerce or consumer brand
  • Bachelor’s degree in UX Design, Graphic Design, Digital Design, or a related field is a plus
  • A strong portfolio showcasing a deep understanding of e-commerce user journeys, alongside exceptional visual/UI design skills required
  • Proficient in industry-standard design and prototyping tools (e.g., Figma, Sketch, Adobe Creative Suite)
  • Deep Knowledge with Shopify or Equivalent Ecommerce Platform: Design with a deep working knowledge of Shopify's architecture, theme system, and constraints. You should know what's achievable in-theme versus what requires custom development, and you should be comfortable making that tradeoff call
Responsibilities
  • Own the Digital Experience End-to-End: Lead the full UX/UI process across all Niagen Bioscience web properties, from research and journey mapping through high-fidelity design, developer specs, QA, and post-launch iteration
  • Optimize the User Journey: Analyze customer behavior to design frictionless, intuitive pathways across the site, focusing on product discovery, education, checkout flow, and subscription management
  • Lead a CRO Program: Plan, design, and prioritize A/B tests across landing pages and key funnel steps. Analyze results across cohorts and turn learnings into a recurring optimization roadmap
  • Elevate Brand Experience: Translate the Tru Niagen brand identity into a premium, cohesive digital experience. Ensure all web touchpoints visually communicate trust, science, and quality
  • Cross-Functional Collaboration: Partner closely with e-commerce, growth marketing, and development teams to ensure designs are technically feasible, aligned with business goals, and optimized for conversion rate (CRO)
  • Graphic & Visual Design: Leverage your graphic design talents to create compelling digital assets, iconography, and visual elements that enhance the overall website aesthetic
  • Collaborate with Creative to Produce Visual Assets: Working closely with the creative team to create digital assets, iconography, illustrations, and visual elements directly for the website
  • Deep Knowledge with Shopify or Equivalent Ecommerce Platform: Design with a deep working knowledge of Shopify's architecture, theme system, and constraints. You should know what's achievable in-theme versus what requires custom development, and you should be comfortable making that tradeoff call
Desired Qualifications
  • Bachelor’s degree in UX Design, Graphic Design, Digital Design, or a related field is a plus
  • Preferred: Strong graphic design talent is a huge plus. We are looking for someone who can actively contribute to the visual storytelling of the brand, not just the layout
  • Project Management & Prioritization: Proven ability to juggle multiple workstreams in a fast-paced environment without compromising quality or deadlines
  • E-commerce Expertise & Curiosity: Deep, functional knowledge of current DTC best practices, paired with an insatiable eagerness to continuously learn and adopt the latest and greatest trends in the e-commerce landscape
  • Journey-Based Testing & Optimization: Deep understanding of landing page optimization and A/B testing methodologies, with the ability to tailor experiments and analyze results across different customer cohorts and distinct user journeys
  • Technical Fluency: Strong technical understanding of front-end capabilities and constraints. You must be able to "speak developer" to effectively translate UX/UI designs into reality and ensure a seamless handoff to the engineering team

Niagen Bioscience focuses on NAD+ science and cellular health, offering Tru Niagen and Niagen Plus consumer products, licensing nicotinamide riboside (NR) to manufacturers, and providing analytical reference standards for research labs. Its flagship ingredient, Niagen, aims to raise cellular NAD+ levels to support mitochondrial function, DNA repair, and metabolism. The company differentiates itself through a 25+-year research history, 35+ human clinical studies, 50+ patents, and partnerships with leading aging biology researchers. Its goal is to extend human healthspan by restoring NAD+ levels and enabling science-based aging interventions across pharma and wellness partnerships.

Company Size

51-200

Company Stage

Post IPO Equity

Headquarters

Los Angeles, California

Founded

1999

Get referred to Niagen Bioscience

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 net sales reached $31.5 million, with 63.5% gross margin.
  • Core e-commerce grew 14% year over year, led by faster direct-to-consumer growth.
  • Niagen Plus launched at-home injections and OneSpaWorld cruise clinics, expanding premium access points.

What critics are saying

  • FDA scrutiny on telehealth prescribing and compounding can shut the at-home injection channel.
  • Retail and supplement incumbents can commoditize NAD+ products and pressure Tru Niagen pricing.
  • Safety, pharmacy, or maritime compliance failures could damage the Niagen Plus brand quickly.

What makes Niagen Bioscience unique

  • Niagen Bioscience owns a 100-plus patent estate around nicotinamide riboside and NAD+ products.
  • USP published NR chloride monograph in May 2026, strengthening Niagen's ingredient standardization moat.
  • The company spans consumer supplements, clinical IVs, telehealth, and ingredient licensing channels.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Wellness Program

Retirement savings with company match

Paid Time Off

Flexible Work Hours

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

4%

2 year growth

0%
The Associated Press
Mar 31st, 2026
Niagen Bioscience partners with OneSpaWorld to offer NAD-boosting IV therapy across 80 cruise ship medi-spas

Niagen Bioscience has partnered with OneSpaWorld to offer pharmaceutical-grade Niagen IV at over 80 medi-spa clinics aboard high-end cruise ships, marking the company's first cruise ship clinic partnership. The collaboration extends Niagen Bioscience's clinical footprint, which already includes over 1,200 healthcare, wellness and longevity clinics across the US. Niagen IV contains pharmaceutical-grade nicotinamide riboside, designed to boost NAD+ levels and support cellular vitality and healthy ageing. The formulation offers 75% shorter infusion times compared to traditional NAD+ IV treatments, with fewer side effects. The partnership introduces a new distribution channel for Niagen Bioscience, targeting health-conscious travellers seeking science-backed wellness experiences. Wells Pharma of Houston will compound and distribute the product to qualified OneSpaWorld locations across the cruise fleet.

Yahoo Finance
Mar 24th, 2026
Niagen Bioscience price target cut to $13 as analysts cite injectable upside but trim optimism

Niagen Bioscience remains in focus after Canaccord analyst Susan Anderson lowered the price target from $14 to $13 whilst maintaining a Buy rating, close to the $13.60 fair value estimate. The firm cited strong demand for Niagen's core business following Q4 results and highlighted potential upside from the injectable segment. The company expanded its share buyback programme by $10 million to $20 million total on 19 March 2026. Niagen launched the Skincare Innovation Lab and introduced Niagen NanoCloud, a waterless topical product using its nicotinamide riboside ingredient. Management issued 2026 sales guidance projecting 10% to 15% year-over-year growth, excluding 2025 revenue from its Analytical Reference Standards division, driven by e-commerce and new partnerships.

The Associated Press
Mar 10th, 2026
Niagen Bioscience launches skincare innovation lab with NanoCloud topical product powered by patented NAD+ booster

Niagen Bioscience has launched Niagen Skincare Innovation Lab and introduced Niagen NanoCloud, its first topical skincare product powered by patented nicotinamide riboside. The limited-release product addresses NAD+ degradation in water-based formulations through sealed, waterless sachets that maintain ingredient stability until use. The dermatologist-tested formula combines Niagen with hyaluronic acid, pullulan, squalane and vitamin E. A six-week consumer study of 37 participants showed visible improvements in skin texture, hydration and radiance within two weeks. The launch positions Niagen Bioscience in the global skincare market, valued at $122.11 billion in 2025 and projected to reach $227.13 billion by 2034. Niagen NanoCloud is available on truniagen.com for $59 per 30-sachet unit.

Business Wire
Mar 10th, 2026
Niagen Bioscience launches topical skincare lab with NanoCloud sachets powered by NAD+ science

Niagen Bioscience has launched Niagen Skincare Innovation Lab, a product platform translating its NAD+ science into skincare, and debuted Niagen NanoCloud, a limited-release topical product powered by its patented nicotinamide riboside ingredient. The dermatologist-tested product addresses NAD+ degradation in water-based formulations through a sealed, waterless sachet format that preserves potency until use. When mixed with serum or moisturiser, it delivers a precision-dosed treatment containing hyaluronic acid, pullulan, squalane and vitamin E. A consumer study showed visible improvements in skin texture and hydration within two weeks. The launch targets the global skincare market, valued at $122 billion in 2025 and projected to reach $227 billion by 2034. Niagen NanoCloud is available at truniagen.com for $59, containing 30 sachets.

Yahoo Finance
Mar 5th, 2026
Niagen Bioscience reports 30% revenue growth to $129.4M in 2025, ends year with $64.8M cash and no debt

Niagen Bioscience reported 16% year-over-year revenue growth in Q4 2025, reaching $33.8 million, whilst full-year 2025 net revenue grew 30% to $129.4 million. The Nasdaq-listed company ended the year with $64.8 million in cash and no debt. The firm secured a patent for nicotinamide riboside and derivatives in intravenous and injectable formulations, initially launching one SKU targeting the biohacker and longevity communities. CEO Rob Fried said the injections would be priced lower than IV treatments. However, Niagen faces challenges including increased competition in the NAD space and FDA uncertainty around NMN's dietary supplement status. Its No Park Parkinson's study failed to achieve its primary endpoint. The company projects more conservative 10-15% growth for 2026, down from 2025's 30%.